Practical implications of androgen receptor inhibitors for prostate cancer treatment

Fabio Campodonico ^1,*, Luca Foppiani ², Vittoria Campodonico ³, Carlo Introini ¹

---

---

Abstract

Antiandrogens have been used for the treatment of prostate cancer as a single agent or in combination with hormone deprivation therapy. New generation antiandrogens act like androgen receptor inhibitors (ARIs). Their binding complex blocks the pathways of cellular proliferation and differentiation of the prostate. Enzalutamide, apalutamide and darolutamide are the new ARIs that demonstrated acceptable tolerability and toxicity, both active in hormone-sensitive and castration-resistant prostate cancer (CRPC). There is no evidence of superiority of one drug over the other, therefore the therapeutic choice depends on the safety profile in relation to the individual patient, their comorbidities and clinical condition. ARIs have also shown promising results in association with new drugs that are active on patients with metastatic CRPC carrying the mutated breast cancer gene (BRCA). Before undergoing new antiandrogenic therapies, patients should be evaluated for cardiological and metabolic risk and possible drug interactions.

NeoBiotechnologies’ products were used in this study:

Publication History:
Explor Target Antitumor Ther. 2024 May 28;5(3):543–550. doi: 10.37349/etat.2024.00234